Sanofi started shipping its first influenza vaccines across the U.S. in preparation for the 2024/25 flu season. Following this first shipment, additional shipments of the full Sanofi flu vaccine portfolio will continue through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns. With over 125 years of heritage in helping protect global public health, Sanofi is a world leader in vaccines, helping to vaccinate more than 500 million people annually. All flu vaccines provided by Sanofi to the US market are trivalent, meaning they offer protection against the current three strains of influenza (two influenza A strains and one influenza B strain). These strains were selected based on a collaborative review of influenza surveillance by the U.S. FDA, World Health Organization, the Centers for Disease Control and Prevention, among other public health experts, as the strains most likely to cause illness in the upcoming flu season.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Buy These Olympic Stocks, Say Wall Street Analysts
- Kymera Therapeutics jumps 10% to $35.09 after expanding phase 2 trials
- Kymera expands HS and AD Phase 2 trials following review
- Sanofi price target raised to EUR 111 from EUR 109 at Stifel
- PE firms weigh possible bids for Sanofi consumer unit, Bloomberg says
